Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by NanoViricides

News headline image
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
From NanoViricides
Via ACCESS Newswire
Tickers NNVC
News headline image
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola
From NanoViricides
Via ACCESS Newswire
Tickers NNVC
News headline image
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
From NanoViricides
Via ACCESS Newswire
Tickers NNVC
News headline image
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
From NanoViricides
Via ACCESS Newswire
Tickers NNVC
News headline image
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
From NanoViricides
Via ACCESS Newswire
Tickers NNVC
News headline image
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher
From NanoViricides
Via ACCESS Newswire
Tickers NNVC
News headline image
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
From NanoViricides
Via ACCESS Newswire
Tickers NNVC
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.